Recurrent ETV6::SYK rearrangement in myeloid malignancies confers partial susceptibility to MEK inhibition
- PMID: 38763512
- DOI: 10.1111/bjh.19549
Recurrent ETV6::SYK rearrangement in myeloid malignancies confers partial susceptibility to MEK inhibition
References
REFERENCES
-
- Kuno Y, Abe A, Emi N, Iida M, Yamamori T, Tanimoto M, et al. An atypical myelodysplastic syndrome with t (9; 12)(q22; p12) and TEL gene rearrangement. Br J Haematol. 1999;106(2):570–571.
-
- Lierman E, Smits S, Debackere K, André M, Michaux L, Vandenberghe P. t (9; 12)(q22; p13) ETV6:: SYK: A new recurrent cytogenetic aberration and tyrosine kinase gene fusion in myeloid or lymphoid neoplasms associated with eosinophilia. Br J Haematol. 2023;200(5):665–668.
-
- De Braekeleer E, Douet‐Guilbert N, Morel F, Le Bris M‐J, Basinko A, De Braekeleer M. ETV6 fusion genes in hematological malignancies: a review. Leuk Res. 2012;36(8):945–961.
-
- Biswas A, Rajesh Y, Mitra P, Mandal M. ETV6 gene aberrations in non‐haematological malignancies: a review highlighting ETV6 associated fusion genes in solid tumors. Biochim Biophys Acta Rev Cancer. 2020;1874(1):188389.
-
- Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022;36(7):1703–1719.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources